Skip to content

    DSK Legal Advises Eris Lifesciences on Velbiom Probiotics Deal

    News

    1. Home
    2. /News

    DSK Legal Advises Eris Lifesciences on Velbiom Probiotics Deal

    DSK Legal acted as counsel for Eris Lifesciences in its strategic acquisition of Velbiom Probiotics' business, expanding its wellness portfolio

    Hydar Choudhury
    Apr 11, 2026·2 min read
    DSK Legal Advises Eris Lifesciences on Velbiom Probiotics Deal

    DSK Legal has acted as the legal counsel for Eris Lifesciences in its successful acquisition of the probiotics business from Velbiom Probiotics. The deal marks a strategic expansion for Eris Lifesciences into the specialized probiotics segment, a rapidly growing niche within the Indian pharmaceutical and wellness market. DSK Legal provided comprehensive legal support, including due diligence, drafting and negotiating the transaction documents, and advising on the regulatory aspects of the acquisition.

    ​The acquisition includes the transfer of a portfolio of brands, products, and related intellectual property focused on gut health and microbiome-based therapies. Velbiom has been recognized for its research-driven approach to probiotics, and this integration is expected to leverage Eris’s robust distribution network and marketing capabilities to scale these products nationally. The move aligns with Eris's ongoing strategy of strengthening its presence in chronic and sub-chronic therapeutic areas through inorganic growth.

    ​The transaction also involved complex negotiations regarding the retention of technical expertise and the seamless transition of manufacturing arrangements. DSK Legal ensured that the intellectual property rights associated with Velbiom's proprietary strains and formulations were fully protected and legally transferred. By securing these assets, Eris is positioned to capitalize on the increasing consumer shift toward preventive healthcare and clinical-grade probiotic supplements.

    ​Beyond the immediate commercial transfer, the deal highlights the increasing consolidation within the Indian healthcare sector, where larger players are actively seeking specialized biotech and wellness startups to diversify their offerings. Legal experts note that such deals require meticulous structuring to balance the valuation of research-heavy assets with the practicalities of pharmaceutical distribution. This successful closure further cements Eris Lifesciences’ position as a major consolidator in the Indian domestic market.

    Explore related legal coverage

    Continue with reporting and analysis connected to this article.

    Browse News

    Related legal topics

    • ELP Advises Max Healthcare Institute on ₹200 Crore Acquisition of Yerawada Properties

      corporate law

    • Bar Body Challenges NCLT Allahabad Filing Framework in High Court

      corporate law

    • JSA, IC RegFin, TTA Advise on Astranova Mobility Series A Fundraise

      Deal Street.

    • First Institutional Fundraise for MOI SOI

      corporate law

    • Lalu Yadav, Rabri Devi, and Tejashwi Yadav to Face Trial as Delhi Court Frames Charges in IRCTC Scam

      News

    • GST Notice By Registered Email Is Valid Service: Delhi HC

      News

    Advertisement

    Hydar Choudhury

    See more from Hydar →
    Jurisight logoJurisight logo

    Simplifying legal knowledge for professionals and citizens. Your daily source for Supreme Court, High Court, and Business Law updates.

    Platform

    HomeAll ArticlesTop NewsSC UpdatesHC Updates

    Categories

    Business LawConstitutionalCriminal LawCivil LawKnow Your Law

    Weekly Digest

    Join 15,000+ others and get the week's most important legal updates.

    © 2026 Jurisight. All rights reserved.
    Privacy PolicyCookie PolicyCookie ConsentLegal Disclaimer